Cidara Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Cidara Therapeutics

30/10/2023 22:05

* Cidara Therapeutics Inc  CDTX.OQ   CDTX.O  is expected
to show a
fall in quarterly revenue when it reports  results 
    * The San Diego California-based  company is expected to
report  a
80.0% decrease in revenue to $8.139 million from $40.74 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Cidara Therapeutics
Inc
is for a loss of 16 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cidara
Therapeutics Inc is $5.5​, above​ its last closing price
of $0.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.10       -0.13      -0.14     Missed  -7.7
 Mar. 31 2023  -0.02       -0.04      0.03      Beat    181.8
 Dec. 31 2022  -0.21       -0.17      -0.19     Missed  -13.4​
 Sep. 30 2022  0.19        0.18       0.17      Missed  -5.6
 ​​Jun.        -0.28       -0.28      -0.19     Beat    32.1
 30 2022                                                
 Mar. 31 2022  -0.28       -0.29      -0.27     Beat    8.2​
 Dec. 31 2021  -0.32       -0.34      -0.26     Beat    24.5
 Sep. 30 2021  -0.36       -0.36      -0.37     Missed  -2.3
 This summary was machine generated October 30 at 22:05 GMT.  All
figures in US dollars  unless otherwise stated